CXCL12 Formulation for Adhesions

About ViCapsys

ViCapsys is a private, pre-revenue biotech leveraging a platform based on the cytokine CXCL12 to locally modulate immune and inflammatory responses. Its lead program aims to enable long-term survival of transplanted pancreatic islet cells to cure Type 1 Diabetes, with supporting data from non-human primate studies. The company is also developing non-cellular applications for diabetic foot ulcers and abdominal adhesions, building on intellectual property licensed from Massachusetts General Hospital.

Therapeutic Areas